Image
Practice Point
Systemic therapy planning considerations – Pregnancy avoidance
Advise women with breast cancer who are receiving chemotherapy, anti-HER2 therapy, or tamoxifen, to avoid pregnancy as these therapies are potentially teratogenic.
Because tamoxifen has an element of teratogenicity, pregnancy during endocrine therapy is not recommended.
How this guidance was developed
This practice point was developed using an expert consensus process. Development of the practice point was informed by a source recommendation in the JBCS 2016 guidelines (Japan) that was not graded by the source guideline authors and based on a non-systematic review of the evidence (the date of the review was not reported).
Related guidance by topic
Systemic therapy planning considerations – Pregnancy avoidance
Practice Point
Advise women with breast cancer who are receiving chemotherapy, anti-HER2 therapy, or tamoxifen, to avoid pregnancy as these therapies are potentially teratogenic.
Principles in action
Patient-centred care
Image
Safe and quality care
Image
Communication
This practice point was developed using an expert consensus process. Development of the practice point was informed by a source recommendation in the JBCS 2016 guidelines (Japan) that was not graded by the source guideline authors and based on a non-systematic review of the evidence (the date of the review was not reported).
Related guidance by topic
Image
